ImmuCell Corporation Share Price

Equities

ICCC

US4525253062

Biotechnology & Medical Research

Market Closed - Nasdaq 02:00:00 27/04/2024 am IST 5-day change 1st Jan Change
5.14 USD +0.78% Intraday chart for ImmuCell Corporation +2.39% +0.98%
Sales 2022 18.57M 1.55B Sales 2023 17.47M 1.46B Capitalization 39.45M 3.29B
Net income 2022 -2M -167M Net income 2023 -5M -417M EV / Sales 2022 2.91 x
Net Debt 2022 6.69M 558M Net Debt 2023 15.71M 1.31B EV / Sales 2023 3.16 x
P/E ratio 2022
-18.9 x
P/E ratio 2023
-6.79 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 71.37%
More Fundamentals * Assessed data
Dynamic Chart
Immucell Corporation Reports Unaudited Sales Results for the Three Months and Twelve Months Ended March 31, 2024 CI
ImmuCell Shares Fall After $20 Million Mixed Securities Shelf Filing MT
Transcript : ImmuCell Corporation, Q4 2023 Earnings Call, Feb 28, 2024
ImmuCell Corporation Enters into an Allonge to and Amendment of Line of Credit with Gorham Savings Bank CI
ImmuCell Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
ImmuCell Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
ImmuCell Corporation Announces Unaudited Sales Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Transcript : ImmuCell Corporation, Q3 2023 Earnings Call, Nov 14, 2023
ImmuCell Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Immucell Corporation Reports Preliminary Unaudited Sales Results for the Third Quarter, Nine Months and Trailing Twelve Months Ended September 30, 2023 CI
Transcript : ImmuCell Corporation, Q2 2023 Earnings Call, Aug 11, 2023
ImmuCell Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Immucell Corporation Reports Preliminary Unaudited Sales Results for the Second Quarter, Six Months and Twelve Months Ended June 30, 2023 CI
ImmuCell Adjusts US FDA Submission Schedule for Re-Tain MT
ImmuCell Corporation Appoints Bryan K. Gathagan to Board of Directors CI
More news
1 day+0.78%
1 week+2.39%
Current month-3.02%
1 month-2.84%
3 months-4.46%
6 months+7.99%
Current year+0.98%
More quotes
1 week
4.82
Extreme 4.82
5.14
1 month
4.82
Extreme 4.82
5.36
Current year
4.71
Extreme 4.71
5.59
1 year
4.26
Extreme 4.26
6.05
3 years
4.26
Extreme 4.26
11.06
5 years
0.00
Extreme 0
13.20
10 years
0.00
Extreme 0
13.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 01/89/01
Director/Board Member 48 01/10/01
Corporate Officer/Principal 68 05/16/05
Members of the board TitleAgeSince
Chief Executive Officer 63 01/89/01
Chairman 67 21/06/21
Director/Board Member 48 01/10/01
More insiders
Date Price Change Volume
26/24/26 5.14 +0.78% 1,776
25/24/25 5.1 +1.19% 6,409
24/24/24 5.04 +0.20% 7,163
22/24/22 5.03 +0.20% 3,262
19/24/19 5.02 -0.59% 3,187

Delayed Quote Nasdaq, April 27, 2024 at 02:00 am IST

More quotes
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing Immediate Immunity against each of the three causes of calf scours (E. coli, coronavirus, and rotavirus).
Calendar
More about the company